BioSpace News Archive

Over the last year, the FDA has issued numerous warnings about the serious risks associated with the use of kratom, including novel risks due to the variability in how kratom products are formulated, sold and used both recreationally and by those who are seeking to self-medicate for pain or to treat opioid withdrawal symptoms

Fagron Sterile Services/JCB Laboratories (FSS/JCB), a leading FDA Registered 503B Outsourcing Facility and a national supplier of compounded sterile preparations, announced plans to expand the company in collaboration with the visionary leadership of the Kansas Department of Commerce.

Jecure Therapeutics Inc., a biotechnology company with novel drug discovery programs targeting serious inflammatory diseases, today announced a definitive agreement by which it will be acquired by Genentech, a member of the Roche Group

The Rogosin Institute (Rogosin), one of the nation’s premier centers for kidney disease care and research, as well as one of the largest not-for-profit dialysis providers in the country, with nine dialysis centers located in Manhattan, Brooklyn, Queens, and the Bronx, announces the opening of the Rogosin Brooklyn Home Dialysis Education and Training Center at 527 Court Street, Brooklyn, New York.

Oncimmune Holdings plc (AIM: ONC.L), a leader in the development, manufacture and commercialization of personalized immunodiagnostics for the screening, detection and care of cancer, today announced that it has entered into an agreement with MultiPlan to expand access to Oncimmune’s EarlyCDT—Lung test.

Life Time, the premier healthy lifestyle brand, is set to open its newest luxury athletic club in Chicagoland in more than ten years.

Scott+Scott Attorneys at Law LLP (“Scott+Scott”), a national shareholder and consumer rights litigation firm, reminds investors that a class action lawsuit has been filed against Nektar Therapeutics (“Nektar” or the “Company”) (NASDAQ: NKTR) and other defendants, related to alleged violations of federal securities laws.

AiPing Pharmaceutical, Inc. announced today that it has completed the sale of three ibuprofen Abbreviated New Drug Applications (ANDAs) in the U.S. to Shandong Xinhua Pharmaceutical Co., Ltd. AiPing will retain sales and distribution rights in the U.S.

Zymeworks Inc. (NYSE/TSX: ZYME), and BeiGene, Ltd. (Nasdaq: BGNE; HKEX: 06160), today announced that the two companies have entered into a strategic collaboration for the clinical development and commercialization of Zymeworks’ investigational ZW25 and ZW49 HER2-targeted bispecific antibodies.

Leading Pharmaceutical companies within the MS space have leveraged the role of the Thought Leader Liaison field personnel as an advantage to capitalize on strategic opportunities.